CD328 (Siglec-7) Antibody, anti-human, REAfinity™
Synonyms: AIRM1, CDw328, D-siglec, QA79, Siglec-7, SIGLEC19P, SIGLECP2, p75, p75/AIRM1
RECOMBINANT EXTENDED VALIDATION
Bioz Star94/100 Bioz rating
19 Citations3 Images
Clone:
REA214 | S7.7
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD328 (Siglec-7) Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
APC-Vio 770
Biotin
FITC
PE
PE-Vio 615
PE-Vio 770
PerCP-Vio 700
Vio Bright R720
VioBlue
Recommended dilution:
1:11
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-101-016, 130-101-013
Description:
Human peripheral blood cells, after erythrocyte lysis, were stained with CD328 (Siglec-7) antibodies as well as with CD56 antibodies and analyzed by flow cytometry using the MACSQuant® Analyzer. Monocytes and lymphocytes were pre-gated for the analysis. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Application image
MICS (MACSima Imaging Cyclic Staining) applications
APC
FITC
PE
Fixation:
frozen – Acetone
Species tested:
human
Recommended dilution:
1:11
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-101-016, 130-101-013
Testing grade:
Extended validation for CD328 (Siglec-7) Antibody, anti-human, REAfinity™
Specificity
Knockout validation

To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.

Extended-Validation detailed information image

Overlay histogram showing flow cytometric analysis of CD328 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD328-PE, clone (REA214). Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Specifications for CD328 (Siglec-7) Antibody, anti-human, REAfinity™
Overview

Clone REA214 recognizes CD328, which is a member of sialic acid-binding immunoglobulin-like lectins (siglecs) family of trans-membrane proteins. Upon recognizing their natural ligands, the sialylated carbohydrates, siglecs generally transmit an inhibitory signal. CD328 is a 75 kDa type I trans-membrane protein and further belongs to the human CD33-related siglec receptors with sialic acid binding N-terminal Ig domain, two C2-set Ig domains, and a cytoplasmic region containing one immune-receptor tyrosine based inhibitory motif (ITIM) and one ITIM-like motif. Expression of CD328 is found on natural killer (NK) cells, monocytes, and on a small subset of CD8+/CD3+ T cells and it preferentially binds (2,8)-linked disialic acids and branched 2,6-sialyl residues.

Additional information: Clone REA214 displays negligible binding to Fc receptors.

Alternative names

AIRM1, CDw328, D-siglec, QA79, Siglec-7, SIGLEC19P, SIGLECP2, p75, p75/AIRM1

Detailed product information

Technical specifications

Clone
REA214
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD328 (Siglec-7)
Distribution of antigen
monocytes, NK cells
Entrez Gene ID
RRID
AB_2657538, AB_2657539, AB_2657536, AB_2657537, AB_2657541, AB_2657540, AB_2657534, AB_2657544, AB_2657542, AB_2657545, AB_2657535, AB_2928422, AB_2928421, AB_2657533, AB_2657543, AB_2657532, AB_2922060, AB_2922093

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD328 (Siglec-7) Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?